Consultant Nuclear Medicine Physician
Department of Radiology, University of Cambridge School of Clinical Medicine
Specialty: Diagnostic and Therapeutic Nuclear Medicine
E-mail: Luigi Aloj :Tel::: +44(0)1223746397
Luigi Aloj graduated from the Universita’ Federico II Medical School (Napoli, ITALY) in 1990. He trained in Nuclear Medicine at the same University obtaining a Specialist Degree in 1994. From 1994 to 1998 he worked in the Nuclear Medicine Department of the National Institutes of Health, USA as a Visiting Fellow and Visiting Associate following research projects on clinical applications of FDG PET, molecular mechanisms of FDG uptake and development of radiopharmaceuticals for oncological applications.
From 1998 to 2003 he was a Researcher at the Centre for Nuclear Medicine of the National Research Council of Italy (Napoli, Italy). During this period he obtained a Specialist Degree in Diagnostic Radiology. Following a six month experience in the Nuclear Medicine Department of the city hospital of Salerno he worked in the Nuclear Medicine Department of the Fondazione Pascale (National Cancer Institute, Napoli, ITALY) from March 2004 to March 2016 where he was the head of the Molecular Imaging Section. Preclinical and clinical research interests during this period were focused on Nuclear Medicine applications in oncology.
From April 2016 he has worked in the Cambridge Biomedical Campus first as an NHS Nuclear Medicine Consultant and since January 2018 as a University Lecturer in the Department of Radiology.
His main research interests are in novel applications of radiolabelled pharmaceuticals for the study and treatment of cancer.
|MD||Universita’ Federico II, Napoli, ITALY||1990|
|Nuclear Medicine||Universita’ Federico II, Napoli, ITALY||1994|
|Radiology||Universita’ Federico II, Napoli, ITALY||2002|
Nuclear Medicine applications in oncology
Best 5 Publications
• Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999 Sep 15;59(18):4709-14.
• Caraco C, Aloj L, Chen LY, Chou JY, Eckelman WC. Cellular release of [18F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem. 2000 Jun 16;275(24):18489-94.
• Aloj L, Aurilio M, Rinaldi V, D’Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, de Jong M. Comparison of the binding and internalization properties of 12 DOTA-coupled and (1)(1)(1)In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1417-25.
• Avallone A, Aloj L, Caraco C, Delrio P, Pecori B, Tatangelo F, Scott N, Casaretti R, Di Gennaro F, Montano M, Silvestro L, Budillon A, Lastoria S. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1848-57.
• Aloj L, D’Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco C, Di Gennaro F, Capobianco G, Giovannoni L, Menssen HD, Neri D, Pinto A, Lastoria S. Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77.
• Avallone A, Delrio P, Aloj L, et al (2009). Combined chemotherapy during preoperative radioation therapy. In: Hayat MA, Methods of cancer diagnosis, therapy and prognosis. p. 411-436, Springer, Berlin.
• Lastoria S, Aloj L, Caracò C, Farese R, Morisco A. (2016) Role of Positron Emission Tomography/Computed Tomography. In: Romano G.M. (eds) Multimodal Treatment of Recurrent Pelvic Colorectal Cancer. Updates in Surgery.p. 39-48. Springer, Milano